TriReme Strategy Bridges Pacific For Medical Device Start-Ups
This article was originally published in Start Up
The road to the rising markets of Asia can be daunting to some medical device start-ups, but not Pleasanton, CA-based TriReme Medical Inc. For the past two years, the privately held maker of balloon-equipped catheters has constructed inroads to Asia through the city-state of Singapore. Two years ago, the company established a subsidiary in Singapore, enabling it to dip into the Asia-based capital pool.
You may also be interested in...
With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.
The proper course of action for treating lesions at bifurcations remains controversial. In the face of numerous small studies with conflicting results and in the absence of large-scale studies investigating whether--or how--to stent the side branch of a bifurcation, cardiologists are searching for solutions. It's all very confusing, but one thing is becoming increasingly clear. Drug-eluting stents, which work so well in straight segments of vessels, aren't working in bifurcated vessels because bifurcations are distinct segments of anatomy, with particular shapes and unique flow characteristics. Start-ups have picked up on the fact that there is a $1 billion interventional cardiology market just waiting to be served with the right technology, and almost a dozen young companies have crowded into the field.
In a much watched and controversial case that may have significant ramifications on the “chilling effects” of generics manufacturers in Israel being deterred from chasing after approvals in which an originator has deceitfully sought to ‘evergreen’ its branded intellectual property, the Israeli Supreme Court has once again come down on the side of the generics industry.